Revenues from next-generation biological drugs will double in 2014, According to A New Report on ASDReports

Monday 2 June 2014, Amsterdam

A new report, now available on ASDReports, predicts the world market for next-generation biologics will grow by more than 50% in 2014. That follows 45% growth in the market in 2013. Double-digit growth is forecast for that worldwide market up to 2024. Those predictions and others appear in Next-Generation Biologics: R&D, Industry and Market 2014-2024.

The new study finds regenerative medicine - including stem cell therapies, gene therapies and tissue-engineered products - accounted for the largest share of the next-generation biologics market in 2013, with revenues close to $1bn in that year. The launch of new stem cell therapies and gene therapies from 2014 will drive growth in the regenerative medicine submarket to 2024. However, in that year, it will only be the second largest segment of the next-generation biologics market. The new report forecasts faster growth for the next-generation antibody and insulin therapy sectors, driven by the launch of pipeline therapies, as well as rising incidence of cancer and diabetes.

Richard Lang, a pharmaceutical industry analyst, said: “Biological therapies have grown to hold a significant position in the treatment of many chronic and serious diseases, including cancer, diabetes and autoimmune diseases. Biologics now account for seven of the 10 bestselling prescription pharmaceuticals, in terms of revenue. This will rise to eight by the end of 2014.

“Next-generation biologics will address shortcomings in the current generation of therapies, including inconvenient dosing and administration, and concerns over side effects. Common developmental trends we identified include sustained release therapies for less frequent dosing and reformulations for oral and topical administration.

“Next-generation biologics that treat new indications will be launched in the coming 10 years. Regenerative medicine offers a novel approach to treating serious acute and chronic diseases, with many late-stage developers targeting cardiovascular disease. Four gene therapies for cardiovascular disease could be launched by 2018. Next-generation antibody fragments and antibody-like proteins offer benefits over current antibody treatments - such as size, multivalency and stability - that allow targeting in new indications and via routes other than injection.”

The new report's data forecasts the world market for next-generation biologics, as well as providing forecasts and other analyses for six leading market sectors, as well as 11 subsectors:

• Next-generation antibodies, including the submarkets of antibody-drug conjugates (ADCs), engineered antibodies and bispecific antibodies
• Next-generation antibody fragments and antibody-like proteins (ALPs)
• Next-generation insulin therapies, including the submarkets of oral insulins, ultra-long acting insulins and ultra-rapid acting insulins
• Regenerative medicine products, including the submarkets of stem cell therapies, gene therapies and tissue-engineered products
• Next-generation growth hormones
• Next-generation recombinant coagulation factors.

The performance of seven next-generation biologics is also assessed by this new report. And forecasts blockbuster revenues for seven next-generation biologics by 2024, including three antibody therapies - Roche’s Kadcyla and Gazyva, and Seattle Genetics/Takeda’s Adcetris - and three novel insulin analogues. In 2024, those seven therapies will achieve revenue of more than $10bn, the report predicts.

That new study also analyses the regional breakdown of next-generation biologics revenues in 2013 and forecasts leading national submarket revenues for the period 2014-2024. The work discusses commercial trends for advanced biological therapies from 2014 to 2024 in the US, Japan and the five leading EU nations. Those seven countries accounted for more than 85% of next-generation biologics revenues in 2013. Early drug launches will create growth of above 25% a year in those submarkets. The report also discusses the outlook for next-generation biologics in India and China, where uptake will be limited in the coming 10 years.

Next-Generation Biologics: R&D, Industry and Market 2014-2024 gives quantitative and qualitative research and analysis of the next-generation biologics market for the period 2014-2024. It also contains interviews conducted with biotechs developing next-generation therapies. That new report adds to the portfolio of studies on the biopharmaceuticals industry and other business in healthcare.